Anticancer Properties of 3-Dietoxyphosphorylfuroquinoline-4,9-dione.

Joanna Drogosz-Stachowicz, Katarzyna Gach-Janczak, Marek Mirowski, Jacek Pietrzak, Tomasz Janecki, Anna Janecka

Open access · goldAbstract read

In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact, top 95% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Joanna Drogosz-StachowiczDepartment of Biomolecular Chemistry, Medical University of Lodz, Mazowiecka 6/8, 92-215 Lodz, Poland.

Katarzyna Gach-JanczakDepartment of Biomolecular Chemistry, Medical University of Lodz, Mazowiecka 6/8, 92-215 Lodz, Poland.ORCID 0000-0002-3129-4158

Marek MirowskiLaboratory of Molecular Diagnostics and Pharmacogenomics, Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Medical University of Lodz, Muszynskiego 1, 90-151 Lodz, Poland.ORCID 0000-0001-9243-0275

Jacek PietrzakLaboratory of Molecular Diagnostics and Pharmacogenomics, Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Medical University of Lodz, Muszynskiego 1, 90-151 Lodz, Poland.ORCID 0000-0002-9187-1199

Tomasz JaneckiInstitute of Organic Chemistry, Lodz University of Technology, Żeromskiego 116, 90-924 Lodz, Poland.ORCID 0000-0002-4898-1405

Anna JaneckaDepartment of Biomolecular Chemistry, Medical University of Lodz, Mazowiecka 6/8, 92-215 Lodz, Poland.

Medical University of Lodz · PLLodz University of Technology · PL

Funding

Medical University of Lodz 503/1-156-02/503-11-001-19-00 and 503/3-015-02/503-31-001-19-00

6 · The paper itself

Abstract

Herein, the antitumor activity of a novel synthetic analog with 5,8-quinolinedione scaffold, diethyl (2-(2-chlorophenyl)-4,9-dioxo-4,9-dihydrofuro [3,2-

Indexed as

Antineoplastic AgentsBreast NeoplasmsAnimalsApoptosisCell Line, TumorCell ProliferationFemaleHumansMCF-7 CellsMiceMice, Inbred C3HAntineoplastic Agentsapoptosiscytotoxic activityDNA damagemaximum tolerated dosequinolinediones

Identifiers

PMID37049894

DOI10.3390/molecules28073128

PMCPMC10095652

OpenAlexW4362469244

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.